ZEOX Zeo ScientifiX, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1557376 · Fiscal year ends 06/30
Financial factors as of 2025-10-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY12.5%
TTM net income YoY-17.3%
TTM EPS YoY-16.2%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—
Margins
Gross margin82.1%
Operating margin-103.6%
Net margin-106.2%
FCF margin-14.3%
EBITDA margin-102.2%
Returns
ROE—
ROA-348.3%
ROIC (approx.)—
Asset turnover3.28x
Leverage & solvency
Liabilities / assets193.2%
Debt / equity—
Current ratio0.33x
Interest coverage-54.96x
Cash quality & payout
Operating cash flow / net income0.13x
Accruals ratio-303.0%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242025-10-31 | FY20242024-10-31 |
|---|---|---|
| Income statement | ||
| Revenue | $5.20M | $4.62M |
| Cost of revenue | $931,000 | $844,000 |
| Gross profit | $4.27M | $3.78M |
| R&D expense | $100,000 | $164,000 |
| SG&A expense | $9.65M | $9.10M |
| Operating income | -$5.39M | -$5.32M |
| Interest expense | $98,000 | $92,000 |
| Net income | -$5.52M | -$4.71M |
| EBITDA | -$5.31M | -$5.25M |
| EPS (basic) | -0.86 | -0.74 |
| EPS (diluted) | -0.86 | -0.74 |
| Weighted avg. shares (diluted) | 6.41M | 6.34M |
| Balance sheet | ||
| Cash & equivalents | $221,000 | $657,000 |
| Receivables | $35,000 | $194,000 |
| Inventory | $423,000 | $232,000 |
| Current assets | $958,000 | $1.17M |
| PP&E, net | $569,000 | $478,000 |
| Total assets | $1.53M | $1.64M |
| Current liabilities | $2.87M | $3.29M |
| Short-term debt | $243,000 | $680,000 |
| Total liabilities | $2.95M | $3.30M |
| Shareholders' equity | -$1.42M | -$1.65M |
| Shares outstanding | 6.75M | 6.34M |
| Cash flow statement | ||
| Operating cash flow | -$718,000 | -$1.45M |
| Capital expenditure | $23,000 | — |
| Free cash flow | -$741,000 | — |
| Investing cash flow | -$23,000 | -$45,000 |
| Financing cash flow | $305,000 | $396,000 |
| Depreciation & amortization | $73,000 | $74,000 |
| Stock-based compensation | $4.69M | $3.85M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.